951784-03-5Relevant articles and documents
Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding
Menichincheri, Maria,Albanese, Clara,Alli, Cristina,Ballinari, Dario,Bargiotti, Alberto,Caldarelli, Marina,Ciavolella, Antonella,Cirla, Alessandra,Colombo, Maristella,Colotta, Francesco,Croci, Valter,Dalessio, Roberto,Danello, Matteo,Ermoli, Antonella,Fiorentini, Francesco,Forte, Barbara,Galvani, Arturo,Giordano, Patrizia,Isacchi, Antonella,Martina, Katia,Molinari, Antonio,Moll, Jürgen K.,Montagnoli, Alessia,Orsini, Paolo,Orzi, Fabrizio,Pesenti, Enrico,Pillan, Antonio,Roletto, Fulvia,Scolaro, Alessandra,Tatò, Marco,Tibolla, Marcellino,Valsasina, Barbara,Varasi, Mario,Vianello, Paola,Volpi, Daniele,Santocanale, Corrado,Vanotti, Ermes
scheme or table, p. 7296 - 7315 (2011/01/12)
Cdc7 serine/threonine kinase is a key regulator of DNA synthesis in eukaryotic organisms. Cdc7 inhibition through siRNA or prototype small molecules causes p53 independent apoptosis in tumor cells while reversibly arresting cell cycle progression in prima
PYRIDYL- AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS
-
, (2008/06/13)
The present invention provides compounds of the formula (I), or the pharmaceutically acceptable salts thereof, wherein G, W, R2, R3, R4, R5 and R6 are as defined in the specification. Further objects